Please login to the form below

Not currently logged in

Lilly's Alimta patent confirmed

A US District Court has confirmed the validity of Eli Lilly's patent for Alimta – a drug used in chemotherapy

The US District Court for the District of Delaware has confirmed the validity of Eli Lilly's patent for Alimta (pemetrexed) – a drug used in chemotherapy.

In the case of Eli Lilly and Company et al v. Teva Parenteral Medicines Inc, the court ruled that Lilly's patent provide protection for Alimta in the US until July 2016. The case followed Teva's abbreviated new drug application (ANDA) to manufacture a generic version of Alimta.

Alimta, used in the treatment of malignant pleural mesothelioma and non-small-cell lung cancer (NSCLC), achieved global sales of $1.64bn over the first three quarters of 2010.

"We are pleased that the District Court has now confirmed the validity of Alimta's compound patent," said Robert A Armitage, senior vice president and general counsel for Lilly. "We continue to emphasise that protection of intellectual property rights is extremely important to the biopharmaceutical industry and the patients we serve.

"These rights provide assurances of market exclusivity that help support the development of the next generation of innovative medicines to treat unmet medical needs."

16th November 2010


Featured jobs

Subscribe to our email news alerts


Add my company
Hayward Medical Communications

Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...